NCT07398859

Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis

A Multi-center, Open-label, Phase II, Single-arm Clinical Study Evaluating the Safety and Efficacy of TQH2722 Injection Combined With Background Treatment in Subjects With Seasonal Allergic Rhinitis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter, open-label, Phase II, single-arm clinical trial, with a planned enrollment of 200 to 300 subjects. Its primary objective is to evaluate the safety and efficacy of TQH2722 injection in the treatment of seasonal allergic rhinitis.

Conditions

• Seasonal Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	TQH2722 injection	TQH2722 injection is a humanized monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα).

Timeline

• Start date: 2026-03-19
• Primary completion: 2026-11-01
• Completion: 2027-03-01
• First posted: 2026-02-10
• Last updated: 2026-03-27

Locations

30 sites across 1 country: China